Literature DB >> 33866361

Dose rate in the highest irradiation area of the rectum correlates with late rectal complications in patients treated with high-dose-rate computed tomography-based image-guided brachytherapy for cervical cancer.

Fumiaki Isohashi1, Yuichi Akino1, Yuri Matsumoto2, Osamu Suzuki1, Yuji Seo1, Keisuke Tamari1, Iori Sumida1, Kenjiro Sawada2, Yutaka Ueda2, Eiji Kobayashi2, Takuji Tomimatsu2, Erina Nakanishi1, Takahisa Nishi1,3, Tadashi Kimura2, Kazuhiko Ogawa1.   

Abstract

The purpose of this study was to evaluate the effect of dose rate to the rectum on late rectal complications in patients treated with computed tomography (CT)-based image-guided brachytherapy (IGBT) for cervical cancer. The subjects were 142 patients with cervical cancer who underwent Ir-192 high-dose-rate (HDR)-IGBT between March 2012 and January 2018. The dose rate to the rectum was calculated using in-house software. The minimum, mean and maximum effective dose rate (EDR) was calculated for voxels of the rectal volume covered by cumulative doses >D0.1cc, >D2cc, and > D5cc. The average EDR of three to four brachytherapy sessions was calculated (EDR for patients; EDRp). The total dose of the rectum was calculated as the biologically equivalent dose in 2-Gy fractions (EQD2). The associations between EDRp for D0.1cc, D2cc, and D5cc and the respective rectal EQD2 values with late rectal complications were then analyzed. The median follow-up period was 40 months. Patients with rectal complications of ≥Grade 1 received a significantly higher mean EDRp for D0.1cc-5cc and had a greater EQD2 for D0.1cc-5cc. Multivariate analysis was performed using the mean EDRp for D2cc, EQD2 for D2cc, heavy smoking and BMI. Of these four variables, mean EDRp for D2cc (HR = 3.38, p = 0.004) and EQD2 for D2cc (HR = 2.59, p = 0.045) emerged as independent predictors for late rectal complications. In conclusion, mean EDRp and EQD2 were associated with late rectal complications in patients treated with HDR CT-based IGBT for cervical cancer.
© The Author(s) 2021. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology.

Entities:  

Keywords:  brachytherapy; complications; intracavity radiotherapy; rectum; uterine cervical neoplasm

Year:  2021        PMID: 33866361      PMCID: PMC8127676          DOI: 10.1093/jrr/rrab023

Source DB:  PubMed          Journal:  J Radiat Res        ISSN: 0449-3060            Impact factor:   2.724


  23 in total

1.  Biologic treatment planning for high-dose-rate brachytherapy.

Authors:  M A Manning; R D Zwicker; D W Arthur; M Arnfield
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-03-01       Impact factor: 7.038

2.  International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG).

Authors:  Akila N Viswanathan; Carien L Creutzberg; Peter Craighead; Mary McCormack; Takafumi Toita; Kailash Narayan; Nicholas Reed; Harry Long; Hak-Jae Kim; Christian Marth; Jacob C Lindegaard; Annmarie Cerrotta; William Small; Edward Trimble
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-12-22       Impact factor: 7.038

3.  The dose-rate effect revisited: radiobiological considerations of importance in radiotherapy.

Authors:  E J Hall; D J Brenner
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-11       Impact factor: 7.038

4.  Rectal dose and source strength of the high-dose-rate iridium-192 both affect late rectal bleeding after intracavitary radiation therapy for uterine cervical carcinoma.

Authors:  Fumiaki Isohashi; Yasuo Yoshioka; Masahiko Koizumi; Osamu Suzuki; Koji Konishi; Iori Sumida; Yutaka Takahashi; Toshiyuki Ogata; Tadayuki Kotsuma; Takehiro Inoue
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-10-14       Impact factor: 7.038

5.  Dose effect relationship for late side effects of the rectum and urinary bladder in magnetic resonance image-guided adaptive cervix cancer brachytherapy.

Authors:  Petra Georg; Richard Pötter; Dietmar Georg; Stefan Lang; Johannes C A Dimopoulos; Alina E Sturdza; Daniel Berger; Christian Kirisits; Wolfgang Dörr
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-02-23       Impact factor: 7.038

6.  Dose-volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: Results from the prospective multicenter EMBRACE study.

Authors:  Renaud Mazeron; Lars U Fokdal; Kathrin Kirchheiner; Petra Georg; Noha Jastaniyah; Barbara Šegedin; Umesh Mahantshetty; Peter Hoskin; Ina Jürgenliemk-Schulz; Christian Kirisits; Jacob C Lindegaard; Wolfgang Dörr; Christine Haie-Meder; Kari Tanderup; Richard Pötter
Journal:  Radiother Oncol       Date:  2016-07-07       Impact factor: 6.280

7.  Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas.

Authors:  Hiram A Gay; H Joseph Barthold; Elizabeth O'Meara; Walter R Bosch; Issam El Naqa; Rawan Al-Lozi; Seth A Rosenthal; Colleen Lawton; W Robert Lee; Howard Sandler; Anthony Zietman; Robert Myerson; Laura A Dawson; Christopher Willett; Lisa A Kachnic; Anuja Jhingran; Lorraine Portelance; Janice Ryu; William Small; David Gaffney; Akila N Viswanathan; Jeff M Michalski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-04-06       Impact factor: 7.038

8.  Correlation of smoking history and other patient characteristics with major complications of pelvic radiation therapy for cervical cancer.

Authors:  Patricia J Eifel; Anuja Jhingran; Diane C Bodurka; Charles Levenback; Howard Thames
Journal:  J Clin Oncol       Date:  2002-09-01       Impact factor: 44.544

9.  Phase III trial comparing two low dose rates in brachytherapy of cervix carcinoma: report at two years.

Authors:  P Lambin; A Gerbaulet; A Kramar; P Scalliet; C Haie-Meder; E P Malaise; D Chassagne
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-02-15       Impact factor: 7.038

10.  A 3-year follow-up study of radiotherapy using computed tomography-based image-guided brachytherapy for cervical cancer.

Authors:  Atsushi Kawashima; Fumiaki Isohashi; Seiji Mabuchi; Kenjiro Sawada; Yutaka Ueda; Eiji Kobayashi; Yuri Matsumoto; Keisuke Otani; Keisuke Tamari; Yuji Seo; Osamu Suzuki; Iori Sumida; Takuji Tomimatsu; Tadashi Kimura; Kazuhiko Ogawa
Journal:  J Radiat Res       Date:  2019-03-01       Impact factor: 2.724

View more
  1 in total

1.  Optimizing the IPSA Conditions to Improve the Treatment Plan Quality in Brachytherapy for Cervical Cancer.

Authors:  Xinglong Yang; Zhouyu Li; Zhantuo Cai; Xi Tang; Jinquan Liu; Shuzhong Cui; Mingyi Li
Journal:  J Oncol       Date:  2022-03-12       Impact factor: 4.375

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.